BIOCRYST PHARMACEUTICALS INC
About BIOCRYST PHARMACEUTICALS INC
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2017
- $25.2M
- Net income
- $263.9M
- Total assets
- $514.2M
- Market cap
- $2.1B
- Gross margin
- 97.8%
- Operating margin
- 39.0%
- Net margin
- 30.2%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $874.8M
- Cost of revenue
- $19.1M
- Gross profit
- $855.8M
- Operating expenses
- $514.8M
- Operating income
- $341.0M
- Income tax
- $3.5M
- Net income
- $263.9M
- EPS (basic)
- $1.26
- EPS (diluted)
- $1.21
Balance sheet
- Total assets
- $514.2M
- Current assets
- $404.3M
- Total liabilities
- $633.3M
- Current liabilities
- $196.1M
- Shareholders’ equity
- -$119.2M
Cash flow
- Operating cash flow
- $347.4M
- Investing cash flow
- -$13.7M
- Financing cash flow
- -$349.9M
- Net cash flow
- -$15.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $2.1B
- P/E ratio
- 7.0
- EPS (diluted)
- $1.21
- Shares outstanding
- 253.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 3, 1994
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $263.9M in FY2017.
- Revenue grew 457% from FY2021 to FY2025.
- Gross margin of 97.8%, net margin 30.2%.
- Trading 25% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 7.0.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review BIOCRYST PHARMACEUTICALS INC.
Write a review
News about BIOCRYST PHARMACEUTICALS INC
News & sentiment via Polygon.io
